Company Description
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as “theranostics”.
We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning.
Our theranostic approach is intended to use imaging and therapy together to “see and treat” cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients.
| Country | Australia |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 415 |
| CEO | Christian Behrenbruch |
Contact Details
Address: 55 Flemington Road North Melbourne, Victoria 3051 Australia | |
| Phone | +61 3 9093 3855 |
| Website | telixpharma.com |
Stock Details
| Ticker Symbol | TLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| IPO Price | $11.87 |
| CIK Code | 0002007191 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| H Kevin McCann | Independent Non-Executive Director and Chairman |
| Andreas Kluge | Non-Executive Director |
| Mark Nelson | Independent Non-Executive Director |
| Tiffany Olson | Independent Non-Executive Director |
| Jann Skinner | Independent Non-Executive Director |
| Christian Behrenbruch | Managing Director and Group CEO |
| Darren Patti | Group Chief Operating Officer |
| Darren Smith | Group Chief Financial Officer |
| David Cade | Group Chief Medical Officer |
| Richard Valeix | Group Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 14, 2024 | RW | Filing |
| Jun 14, 2024 | RW | Filing |
| Jun 10, 2024 | 8-A12B | Registration of securities |
| Jun 5, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| May 30, 2024 | F-6 | Filing |
| May 17, 2024 | F-1 | Registration statement for certain foreign private issuers |
| May 9, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 15, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 15, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 2, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |